Abstract
The use of non‑steroidal anti‑inflammatory drugs (NSAIDs) has been associated with a reduced risk of various types of cancer, including esophageal cancer. However, the mechanisms underlying the antineoplastic effects of NSAIDs in esophageal cancer remain to be elucidated. In the present study, a significant inhibition in cell viability was observed in the EC109 cells following treatment with different concentrations of indomethacin, and these effects occurred in a dose‑ and time‑dependent manner. This inhibition was due to the release of second mitochondria‑derived activator of caspase (Smac) into the cytosol and the activation of caspase‑3. Subsequently, flow cytometry was performed to investigate indomethacin‑induced apoptosis following the overexpression or knockdown of Smac, and western blot analysis was performed to determine the expression of Smac and the activation of caspase‑3. Overexpression of Smac was promoted apoptosis, while downregulation of Smac significantly inhibited apoptosis. Western blot analysis demonstrated that indomethacin induced apoptosis through releasing Smac into the cytosol and activating caspase‑3. These results indicated that Smac is essential for the apoptosis induced by indomethacin in esophageal cancer cells.
Introduction
Esophageal cancer remains a significant global health challenge characterized by high mortality rates and limited therapeutic options. While epidemiological data and clinical trials have long suggested that non-steroidal anti-inflammatory drugs (NSAIDs) like indomethacin can significantly reduce the risk of developing this cancer, the precise molecular machinery behind this protective effect has remained largely unknown. This study investigates the role of the mitochondrial apoptotic pathway, specifically focusing on the protein Smac (Second Mitochondria-derived Activator of Caspase), in the human EC109 esophageal cancer cell line.
Methods
The researchers utilized the human EC109 esophageal cancer cell line and employed several key techniques:
- Cell Viability & Apoptosis Assays: MTT assays measured metabolic activity, while flow cytometry quantified the percentage of cells undergoing apoptosis.
- Protein Analysis: Western blotting tracked the expression and localization of Smac and caspase-3. Cellular fractionation was used to separate cytosolic and mitochondrial proteins.
- Genetic Manipulation: To prove Smac's necessity, the team used overexpression (via a pcDNA3.1-Smac vector) and knockdown (via siRNA) to modulate Smac levels.
Results
Indomethacin Triggers Smac Translocation and Caspase-3 Activation
A critical finding of the study is that indomethacin treatment causes Smac to leak from the mitochondria into the cytosol. In healthy cells, Smac is sequestered within the mitochondria. As shown in Figure 1, indomethacin treatment leads to a time-dependent increase in cytosolic Smac and a corresponding decrease in mitochondrial Smac. This translocation serves as the "on-switch" for the executioner enzyme, caspase-3, which is converted from its inactive pro-form to its active form.
Smac is Essential for the Anti-Cancer Effect
To confirm that Smac is necessary for indomethacin-induced cell death, the researchers used siRNA to "silence" the Smac gene. As demonstrated in Figure 2, knocking down Smac significantly reduced the effectiveness of indomethacin. While indomethacin reduced viability in control cells, those with silenced Smac remained significantly more viable at various drug concentrations. This functional "rescue" proves that Smac is a linchpin in the drug's mechanism of action.
Discussion and Conclusion
The study provides a clear mechanistic pathway: indomethacin induces apoptosis by triggering the release of Smac into the cytosol, which then activates caspase-3. While these results are promising, they are currently limited to in vitro cell culture. High doses of indomethacin can cause significant gastrointestinal side effects in patients. However, the authors suggest that Smac mimetics—small molecules that mimic Smac's function—could potentially be used alongside lower, safer doses of NSAIDs to achieve the same anti-cancer effect. This research identifies Smac as a critical target for future therapeutic strategies in esophageal cancer.
Summary updated